SCHEMBL10047095

SCHEMBL10047095

CC(C)(C)OC(=O)NCNc1nc2[nH]cnc2c(=O)[nH]1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.42
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ CACNA1H O95180 1/20 0.38
▸ CACNA1B Q00975 1/20 0.38
▸ CACNA1C Q13936 1/20 0.38
▸ JAK1 P23458 2/20 0.36
▸ STK17B O94768 1/20 0.35
▸ STK17A Q9UEE5 1/20 0.35
▸ NPSR1 Q6W5P4 4/20 0.35
▸ TDP1 Q9NUW8 2/20 0.35
▸ ATM Q13315 1/20 0.35
▸ MAPT P10636 3/20 0.35
▸ RECQL P46063 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ XDH P47989 2/20 0.34
▸ GDA Q9Y2T3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183292 0.90 BCHE (0.55) BCHEL3MBTL1CACNA1HCACNA1BCACNA1C
SCHEMBL609127 0.88 BCHE (0.47) BCHEL3MBTL1STK17BSTK17ANPSR1
SCHEMBL610056 0.86 BCHE (0.46) BCHEL3MBTL1CACNA1HCACNA1BCACNA1C
SCHEMBL28469810 0.84 GDA (0.42) BCHEL3MBTL1CACNA1HCACNA1BCACNA1C
SCHEMBL10073542 0.83 BCHE (0.44) BCHEL3MBTL1STK17BSTK17ANPSR1
SCHEMBL10073929 0.82 CCNE2 (0.38) BCHEL3MBTL1CACNA1HCACNA1BCACNA1C
SCHEMBL10047090 0.77 L3MBTL1 (0.42) BCHEL3MBTL1STK17BSTK17ANPSR1
SCHEMBL5062459 0.74 XDH (0.46) MEN1KMT2APOLBXDHGDA
SCHEMBL10047093 0.73 TSHR (0.42) BCHEMEN1KMT2A
SCHEMBL16573451 0.72 SMN1; SMN2 (0.59) L3MBTL1MAPTMEN1KMT2AGDA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895734-B2 Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid OLIPASS CORPORATION (KR) 2014-11-25 — — US disclosed
US-8884008-B2 Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid OLIPASS CORPORATION (KR) 2014-11-11 — — US disclosed
US-20140323728-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2014-10-30 — — US disclosed
US-8859766-B2 Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid OLIPASS CORPORATION (KR) 2014-10-14 — — US disclosed
US-20140155604-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2014-06-05 — — US disclosed
US-20140155605-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2014-06-05 — — US disclosed
US-8680253-B2 Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid OLIPASS CORPORATION (KR) 2014-03-25 — — US disclosed
US-20120040918-A9 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2012-02-16 — — US disclosed
US-20110178031-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2011-07-21 — — US disclosed
WO-2009113828-A9 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2009-11-05 — — WO disclosed
WO-2009113828-A2 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID CTI BIO (KR) 2009-09-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323728-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID SLC7A1, SLC29A1, SLC43A3 BCHE 4726/4885L3MBTL1 1049/4885CACNA1H 3843/4885
US-20140155605-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID SLC7A1, SLC29A1, SLC43A3 BCHE 4726/4885L3MBTL1 1049/4885CACNA1H 3843/4885
US-20120040918-A9 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID SLC7A1, SLC29A1, SLC43A3 BCHE 4726/4885L3MBTL1 1049/4885CACNA1H 3843/4885
US-20110178031-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID SLC7A1, SLC29A1, SLC43A3 BCHE 4726/4885L3MBTL1 1049/4885CACNA1H 3843/4885
US-20140155604-A1 PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID SLC7A1, SLC29A1, SLC43A3 BCHE 4726/4885L3MBTL1 1049/4885CACNA1H 3843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback